We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Iceland Genomics and Aclara in Biomarker Alliance

By Labmedica staff writers
Posted on 17 Dec 2004
Print article
An agreement to validate candidate biomarkers and their utility as indicators of disease progression and predictors of response to therapy has been announced by Iceland Genomics Corp. (IGC, Reykjavik, Iceland) and Aclara BioSciences (Mountain View, CA, USA).

Under the agreement Aclara will utilize its proprietary eTag assays to analyze tumor samples from cancer patients provided by IGC to validate candidate biomarkers. ICG will also provide blood samples and blinded patient data, including treatment histories and outcomes. Aclara will provide funding to IGC and will share the data from the study with IGC for incorporation into its database.

Aclara's eTAG assays are able to identify difficult-to-detect protein complexes that can provide unique insights as to the likelihood of particular patients to respond to specific therapies. In addition, since eTag assays can utilize formalin-fixed paraffin-embedded clinical samples, the standard format in most pathology laboratories, this will enable the analysis of both archived samples from initial biopsies or surgeries as well as freshly collected materials.

The biomarkers under evaluation are proteins and protein complexes and their different functional or activation states that comprise signaling pathways in cells. These pathways enable information transfer within and between cells, and control such processes as cell growth, division, and death. When these pathways malfunction, the affected cells can become cancerous, dividing uncontrollably. By measuring the targeted proteins and pathways directly, Aclara believes it can help doctors better determine whether certain therapies are more appropriate for individual cancer patients.

"There is clearly a need for better methods to assess cancer patients, both from a preferred treatment and ultimate prognosis perspective,” said Dana Hosseini, chief executive officer of Iceland Genomics. "We look forward to the results of this study, and seeing how they correlate with other measures used to evaluate these samples at Iceland Genomics.”



Related Links:
Iceland Genomics
Alcara Biosciences
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test
New
Hepatitis B Virus Test
HBs Ab – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.